Precision Medicine in Oncology® | Specialty

Dr. Jackman on Overcoming Resistance to EGFR Inhibitors in Lung Cancer

March 27th 2017

David M. Jackman, MD, medical director of Clinical Pathways, Dana-Farber Cancer Institute, assistant professor of Medicine, Harvard Medical School, discusses overcoming resistance to EGFR inhibitors in non–small cell lung cancer (NSCLC).

Dr. Swisher on Efficacy Results of ARIEL 2 Study in Ovarian Cancer

March 24th 2017

Elizabeth Swisher, MD, professor, Department of Medicine, Division of Medical Genetics, University of Washington School of Medicine, Breast and Ovarian Cancer Prevention Program, Seattle Cancer Care Alliance, discusses the results of the ARIEL2 trial in patients in patients with relapsed, platinum-sensitive, high-grade ovarian carcinoma with a germline or somatic BRCA mutation.

Maintenance Olaparib Shows Impressive PFS Benefit for BRCA+ Ovarian Cancer

March 15th 2017

Maintenance therapy with olaparib showed a 70% reduction in the risk of progression or death compared with placebo for patients with platinum-sensitive, relapsed, BRCA-mutant ovarian cancer.

Carboplatin Hypersensitivity Linked to BRCA Deficiency in Ovarian Cancer

March 14th 2017

Treatment with a carboplatin desensitization regimen led to improved overall survival in patients with BRCA-proficient ovarian cancer.

MMR Deficiency Linked to PD-L1 Expression in Endometrial Cancer

March 14th 2017

Mismatch repair-deficient endometrial cancers exhibited significantly higher levels of PD-L1 expression compared with MMR-intact tumors.

New Insights Into Rucaparib Activity in Ovarian Cancer

March 13th 2017

The PARP inhibitor rucaparib slowed progression of relapsed BRCA-mutant ovarian cancer regardless of whether the mutations were somatic or germline, a new analysis of a phase II trial showed.

Gomella Discusses Ongoing Progress With Genetic Testing in Prostate Cancer

March 11th 2017

Leonard Gomella, MD, discusses the current state and critical next steps for optimizing genetic testing in prostate cancer.

Butterfly Effect May Foil Genomic Medicine

March 11th 2017

The so-called butterfly effect, in which a small creature can cause something on the scale of an earthquake merely by flapping its wings, is fodder for debate on whether the digital revolution in medicine can deliver on its promise for precision medicine.

Breast Surgeons Essential for Effective Genetic Testing

March 10th 2017

It is imperative that surgeons remain involved in genetic counseling to meet the immense unmet need that exists for patients with breast cancer, given a shortage of available genetic counselors.

Petrylak Discusses Significance of Genetic Testing in Prostate Cancer

March 8th 2017

Daniel Petrylak, MD, discusses the significance of genetics in the future of prostate cancer care and highlights emerging treatments and challenges in the field.

Dr. Kane on High-Penetrance Genetic Syndromes in Prostate Cancer

March 8th 2017

Christopher J. Kane, MD, professor of Surgery, chair, Department of Urology, UC San Diego Health, discusses high-penetrance genetic syndromes in patients with prostate cancer.

Dr. Drilon on NTRK Rearrangement in Lung Cancer

March 3rd 2017

Alexander Drilon, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses NTRK rearrangement in patients with lung cancer.

Expert Discusses Biomarkers for PARP Inhibitors in Ovarian Cancer

February 20th 2017

Dr. Elizabeth Swisher discusses biomarkers for PARP inhibitors and the evolving role of these agents in ovarian cancer.

Olaparib Improves PFS in Phase III BRCA+ Breast Cancer Trial

February 17th 2017

The PARP inhibitor olaparib improved progression-free survival versus standard chemotherapy in patients with BRCA-positive, HER2-negative breast cancer, according to findings from the phase III OLYMPIAD trial.

Assays Break New Ground in Oncology

February 16th 2017

Two novel imaging agents and 6 clinical assays for use in cancer care gained the FDA's approval in 2016, marking advances in the diagnostic field.

Precision Medicine and the Future of Pancreatic Cancer

February 16th 2017

PEGPH20 in Advanced Pancreatic Cancer

February 16th 2017

The Potential for Immunotherapy in Pancreatic Cancer

February 16th 2017

Adjuvant Therapy in Pancreatic Cancer

February 16th 2017

Considerations in Locally Advanced Pancreatic Cancer

February 16th 2017